Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease

Jan Wysocki, Anne Goodling, Mar Burgaya, Kathryn Whitlock, John Ruzinski, Daniel Batlle, Maryam Afkarian

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    The pathways implicated in diabetic kidney disease (DKD) are largely derived from animal models. To examine if alterations in renin-angiotensin system (RAS) in humans are concordant with those in rodent models, we measured concentration of angiotensinogen (AOG), cathepsin D (CTSD), angiotensinconverting enzyme (ACE), and ACE2 and enzymatic activities of ACE, ACE2, and aminopeptidase-A in FVB mice 13-20 wk after treatment with streptozotocin (n = 9) or vehicle (n = 15) and people with long-standing type 1 diabetes, with (n = 37) or without (n = 81) DKD. In streptozotocin-treated mice, urine AOG and CTSD were 10.4-and 3.0-fold higher than in controls, respectively (P < 0.001). Enzymatic activities of ACE, ACE2, and APA were 6.2-, 3.2-, and 18.8-fold higher, respectively, in diabetic animals (P < 0.001). Angiotensin II was 2.4-fold higher in diabetic animals (P = 0.017). Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g). In people with DKD, urine ACE concentration was 1.8-fold higher (1.4 vs. 0.8 μg/g in those without DKD), while its enzymatic activity was 0.6-fold lower (1.0 vs. 1.6 × 109 RFU/g in those without DKD). Lower ACE activity, but not ACE protein concentration, was associated with ACE inhibitor (ACEI) treatment. After adjustment for clinical covariates, AOG, CTSD, ACE concentration, and ACE activity remained associated with DKD. In conclusion, in mice with streptozotocin-induced diabetes and in humans with DKD, urine concentrations and enzymatic activities of several RAS components are concordantly increased, consistent with enhanced RAS activity and greater angiotensin II formation. ACEI use was associated with a specific reduction in urine ACE activity, not ACE protein concentration, suggesting that it may be a marker of exposure to this widely-used therapy.

    Original languageEnglish (US)
    Pages (from-to)F487-F494
    JournalAmerican Journal of Physiology - Renal Physiology
    Volume313
    Issue number2
    DOIs
    StatePublished - Aug 2 2017

    Fingerprint

    Diabetic Nephropathies
    Renin-Angiotensin System
    Type 1 Diabetes Mellitus
    Chronic Renal Insufficiency
    Urine
    Angiotensinogen
    Cathepsin D
    4 alpha-glucanotransferase
    Enzymes
    Streptozocin
    Angiotensin II
    Glutamyl Aminopeptidase
    Experimental Diabetes Mellitus
    Enzyme Inhibitors
    Angiotensin-Converting Enzyme Inhibitors
    Rodentia
    Proteins
    Animal Models

    Keywords

    • Aminopeptidase-A
    • Angiotensin-converting enzyme
    • Angiotensin-converting enzyme 2
    • Angiotensinogen
    • Cathepsin D
    • Diabetic kidney disease
    • Renin-angiotensin system

    ASJC Scopus subject areas

    • Physiology
    • Urology

    Cite this

    Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. / Wysocki, Jan; Goodling, Anne; Burgaya, Mar; Whitlock, Kathryn; Ruzinski, John; Batlle, Daniel; Afkarian, Maryam.

    In: American Journal of Physiology - Renal Physiology, Vol. 313, No. 2, 02.08.2017, p. F487-F494.

    Research output: Contribution to journalArticle

    Wysocki, Jan ; Goodling, Anne ; Burgaya, Mar ; Whitlock, Kathryn ; Ruzinski, John ; Batlle, Daniel ; Afkarian, Maryam. / Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. In: American Journal of Physiology - Renal Physiology. 2017 ; Vol. 313, No. 2. pp. F487-F494.
    @article{11449d631e1e4880a008aef9e7c946f6,
    title = "Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease",
    abstract = "The pathways implicated in diabetic kidney disease (DKD) are largely derived from animal models. To examine if alterations in renin-angiotensin system (RAS) in humans are concordant with those in rodent models, we measured concentration of angiotensinogen (AOG), cathepsin D (CTSD), angiotensinconverting enzyme (ACE), and ACE2 and enzymatic activities of ACE, ACE2, and aminopeptidase-A in FVB mice 13-20 wk after treatment with streptozotocin (n = 9) or vehicle (n = 15) and people with long-standing type 1 diabetes, with (n = 37) or without (n = 81) DKD. In streptozotocin-treated mice, urine AOG and CTSD were 10.4-and 3.0-fold higher than in controls, respectively (P < 0.001). Enzymatic activities of ACE, ACE2, and APA were 6.2-, 3.2-, and 18.8-fold higher, respectively, in diabetic animals (P < 0.001). Angiotensin II was 2.4-fold higher in diabetic animals (P = 0.017). Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g). In people with DKD, urine ACE concentration was 1.8-fold higher (1.4 vs. 0.8 μg/g in those without DKD), while its enzymatic activity was 0.6-fold lower (1.0 vs. 1.6 × 109 RFU/g in those without DKD). Lower ACE activity, but not ACE protein concentration, was associated with ACE inhibitor (ACEI) treatment. After adjustment for clinical covariates, AOG, CTSD, ACE concentration, and ACE activity remained associated with DKD. In conclusion, in mice with streptozotocin-induced diabetes and in humans with DKD, urine concentrations and enzymatic activities of several RAS components are concordantly increased, consistent with enhanced RAS activity and greater angiotensin II formation. ACEI use was associated with a specific reduction in urine ACE activity, not ACE protein concentration, suggesting that it may be a marker of exposure to this widely-used therapy.",
    keywords = "Aminopeptidase-A, Angiotensin-converting enzyme, Angiotensin-converting enzyme 2, Angiotensinogen, Cathepsin D, Diabetic kidney disease, Renin-angiotensin system",
    author = "Jan Wysocki and Anne Goodling and Mar Burgaya and Kathryn Whitlock and John Ruzinski and Daniel Batlle and Maryam Afkarian",
    year = "2017",
    month = "8",
    day = "2",
    doi = "10.1152/ajprenal.00074.2017",
    language = "English (US)",
    volume = "313",
    pages = "F487--F494",
    journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
    issn = "1931-857X",
    publisher = "American Physiological Society",
    number = "2",

    }

    TY - JOUR

    T1 - Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease

    AU - Wysocki, Jan

    AU - Goodling, Anne

    AU - Burgaya, Mar

    AU - Whitlock, Kathryn

    AU - Ruzinski, John

    AU - Batlle, Daniel

    AU - Afkarian, Maryam

    PY - 2017/8/2

    Y1 - 2017/8/2

    N2 - The pathways implicated in diabetic kidney disease (DKD) are largely derived from animal models. To examine if alterations in renin-angiotensin system (RAS) in humans are concordant with those in rodent models, we measured concentration of angiotensinogen (AOG), cathepsin D (CTSD), angiotensinconverting enzyme (ACE), and ACE2 and enzymatic activities of ACE, ACE2, and aminopeptidase-A in FVB mice 13-20 wk after treatment with streptozotocin (n = 9) or vehicle (n = 15) and people with long-standing type 1 diabetes, with (n = 37) or without (n = 81) DKD. In streptozotocin-treated mice, urine AOG and CTSD were 10.4-and 3.0-fold higher than in controls, respectively (P < 0.001). Enzymatic activities of ACE, ACE2, and APA were 6.2-, 3.2-, and 18.8-fold higher, respectively, in diabetic animals (P < 0.001). Angiotensin II was 2.4-fold higher in diabetic animals (P = 0.017). Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g). In people with DKD, urine ACE concentration was 1.8-fold higher (1.4 vs. 0.8 μg/g in those without DKD), while its enzymatic activity was 0.6-fold lower (1.0 vs. 1.6 × 109 RFU/g in those without DKD). Lower ACE activity, but not ACE protein concentration, was associated with ACE inhibitor (ACEI) treatment. After adjustment for clinical covariates, AOG, CTSD, ACE concentration, and ACE activity remained associated with DKD. In conclusion, in mice with streptozotocin-induced diabetes and in humans with DKD, urine concentrations and enzymatic activities of several RAS components are concordantly increased, consistent with enhanced RAS activity and greater angiotensin II formation. ACEI use was associated with a specific reduction in urine ACE activity, not ACE protein concentration, suggesting that it may be a marker of exposure to this widely-used therapy.

    AB - The pathways implicated in diabetic kidney disease (DKD) are largely derived from animal models. To examine if alterations in renin-angiotensin system (RAS) in humans are concordant with those in rodent models, we measured concentration of angiotensinogen (AOG), cathepsin D (CTSD), angiotensinconverting enzyme (ACE), and ACE2 and enzymatic activities of ACE, ACE2, and aminopeptidase-A in FVB mice 13-20 wk after treatment with streptozotocin (n = 9) or vehicle (n = 15) and people with long-standing type 1 diabetes, with (n = 37) or without (n = 81) DKD. In streptozotocin-treated mice, urine AOG and CTSD were 10.4-and 3.0-fold higher than in controls, respectively (P < 0.001). Enzymatic activities of ACE, ACE2, and APA were 6.2-, 3.2-, and 18.8-fold higher, respectively, in diabetic animals (P < 0.001). Angiotensin II was 2.4-fold higher in diabetic animals (P = 0.017). Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g). In people with DKD, urine ACE concentration was 1.8-fold higher (1.4 vs. 0.8 μg/g in those without DKD), while its enzymatic activity was 0.6-fold lower (1.0 vs. 1.6 × 109 RFU/g in those without DKD). Lower ACE activity, but not ACE protein concentration, was associated with ACE inhibitor (ACEI) treatment. After adjustment for clinical covariates, AOG, CTSD, ACE concentration, and ACE activity remained associated with DKD. In conclusion, in mice with streptozotocin-induced diabetes and in humans with DKD, urine concentrations and enzymatic activities of several RAS components are concordantly increased, consistent with enhanced RAS activity and greater angiotensin II formation. ACEI use was associated with a specific reduction in urine ACE activity, not ACE protein concentration, suggesting that it may be a marker of exposure to this widely-used therapy.

    KW - Aminopeptidase-A

    KW - Angiotensin-converting enzyme

    KW - Angiotensin-converting enzyme 2

    KW - Angiotensinogen

    KW - Cathepsin D

    KW - Diabetic kidney disease

    KW - Renin-angiotensin system

    UR - http://www.scopus.com/inward/record.url?scp=85026846888&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85026846888&partnerID=8YFLogxK

    U2 - 10.1152/ajprenal.00074.2017

    DO - 10.1152/ajprenal.00074.2017

    M3 - Article

    C2 - 28468961

    AN - SCOPUS:85026846888

    VL - 313

    SP - F487-F494

    JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

    JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

    SN - 1931-857X

    IS - 2

    ER -